Board of Directors

Mr. Adams is Co-founder & Partner at MintPharma Capital, which led Vycellix’s most recent March 2024 funding round. He has more than 30 years of experience in investment management. Currently, he serves as the managing partner of Mint12, a specialized alternative investment management company. Under his guidance, Mint12 oversees the management of two real estate lending funds and two real estate equity funds. Before establishing Mint12, Dave held the position of Managing Partner and Founder at Fluid Capital Management (FCM), a company he established in 2010. At FCM, he successfully managed various alternative investment portfolios. Before his tenure at FCM, Dave worked as an interest rate derivatives trader at the Chicago Mercantile Exchange (CME) from 1991 to 2010. During these 20 years, he efficiently managed substantial proprietary and investor capital. Mr. Adams initiated his career in 1987 at Deloitte Haskins & Sells. In 1987, he graduated Cum Laude from Indiana University with a Bachelor of Science degree in Accounting.

Mr. Finizio is Co-founder & Partner at MintPharma Capital, which led Vycellix’s most recent March 2024 funding round. He also co-founded CareFusion, the market leader in medication patient safety in 2001, which he sold to Cardinal Health (CAH) in 2006. After CareFusion, Rob co-founded TherapeuticsMD (Nasdaq: TXMD) in 2008. As the CEO and Vice Chairman, he developed TXMD from a start-up to the market leader in women’s health pharmaceutical development. TXMD is the first and only women’s health pharmaceutical company to have three new drugs approved in a single year (2018). In 2013, Rob took TXMD public on the New York Stock Exchange and achieved a market capitalization of well over a billion dollars. During his tenure at TXMD, Rob raised more than $1 Billion dollars through public equity and debt. Rob also currently serves as a board member and Executive Director of PleoPharma, Myosin Therapeutics and Zyversa (Nasdaq: ZVSA).

Dr. Streeter is a Partner at DeepWork Capital, a venture capital firm based in Florida, which co-participated in Vycellix’s most recent March 2024 funding round. Dr. Streeter also has a dual role as the Director of Ventures at the University of Florida. Previously, he founded the medical technology companies, PhotoThera and American Veterinary Laser, and he was the CEO of Banyan Biomarkers. He also served as SVP, Corporate Development & Strategy at Quanterix (Nasdaq: QTRX) and as CEO of the Institute for the Commercialization of Public Research, which has the mission of funding early-stage companies throughout the State of Florida. Dr. Streeter’s Board appointments have included Florida Research Consortium, Governor’s Life Science Task Force for the State of Florida, FBI Counter Terrorism Southeast Working Group, Walter H. Coulter Center Committee at the University of Miami, and the Gainesville Chamber of Commerce Board of Directors. He earned his B.S. in Biology from the University of Nevada Reno and his M.D. from the University of Nevada School of Medicine. He’s the inventor of more than 20 patents and has authored numerous scientific publications. Prior to entering industry, Dr. Streeter served as an Officer in the U.S. Navy where he became the first Navy Flight Surgeon selected as a TOPGUN instructor.

Governor Thompson served as the University of Wisconsin System President from 2020 to 2022. He is the former U.S. Health and Human Services (HHS) Secretary, serving from 2001 to 2005, and a four-term Governor of Wisconsin. From 2005 to 2009, he served as a senior advisor at the consulting firm Deloitte & Touche USA LLP and was the founding independent chairman of the Deloitte Center for Health Solutions. From 2005 to 2012, Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP. He served as Chairman of the Board of Trustees of Logistics Health, Inc. from January 2007 to May 2011, and served as President from February 2005 to January 2011. Governor Thompson has served on the boards of United Therapeutics Corporation (Nasdaq: UTHR) since 2010 and TherapeuticsMD, Inc. (Nasdaq: TXMD) since 2012. He was formerly the Chairman of the Board of Trustees at Physicians Realty Trust from 2013 until its merger with Healthpeak Properties (NYSE: DOC), in 2024. Governor Thompson also previously served on the boards of Scilex Holding Company (Nasdaq: SCLX), Tyme Technologies, Inc. (formerly Nasdaq: TYME), Cancer Genetics, Inc. (now Vyant Bio, Inc., formerly Nasdaq: VYNT), Cytori Therapeutics, Inc. (now Plus Therapeutics, Nasdaq: PSTV), CareView Communications, Inc., C.R. Bard, Inc. (formerly NYSE: BCR) and Centene Corporation (NYSE: CNC).